Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAX 855 prophylaxis versus on-demand treatment in previously treated patients with severe hemophilia A
NL-OMON39872Phase 3Active, not recruiting
- Sponsor
- Baxter International Inc.
- Start
- Dec 2013
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of rurioctocog alfa pegol in hemophilia A (2 arms), sponsored by Baxter International Inc. Primary endpoint: Annualized bleed rate. Started Dec 2013; status: active, not recruiting.
02
Drugs
rurioctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON39872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39872.